Johnson & Johnson’s JNJ-6143 posted excellent results in an early-stage clinical trial.
For income investors, the real story is a Dividend King with a deep lineup and pipeline.
Last year, Johnson & Johnson (NYSE: JNJ) acquired a smaller biotech, Halda Therapeutics, in a cash transaction valued at $3.05 billion. The key asset from that transaction was JNJ-6143, an investigational, early stage candidate for prostate cancer. It will take time to determine whether this acquisition was worth it for Johnson & Johnson, but recent clinical developments suggest that the $3.05 billion the pharmaceutical giant spent may have been well spent. Let me explain.
Image source: The Motley Fool.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
JNJ-6143 is part of an experimental class of cancer medicines called Regulated Induced Proximity Targeting Chimera, which use proteins found in cancer cells to disrupt certain functions those cells need to survive. This approach could lead to much stronger efficacy than existing standards of care for certain cancers. Johnson & Johnson's JNJ-6143 showed the potential of these therapies in a Phase 1 clinical trial, the results of which it presented at the European Society for Medical Oncology 2026 Congress, held in Madrid in October.
The medicine was tested in patients with metastatic castration-resistant prostate cancer. Notably, these patients had received a median of four prior therapies, so we aren't dealing with an easy-to-treat cancer. Yet, JNJ-6143 performed extremely well. It led to an overall response rate (the percentage of patients who respond to treatment) of 75% among patients with measurable disease. This data is highly encouraging. Of course, this was only an early stage study. There is a long road ahead before JNJ-6143 earns approval, that is, if it performs well in future clinical studies.
However, this once again highlights the strength of Johnson & Johnson's pipeline. The company has successfully expanded its lineup of approved drugs in recent years, with newer launches such as Imaavy, which treats generalized myasthenia gravis, and Icotyde, a therapy for plaque psoriasis.
These newer launches could help the company overcome headwinds, such as government-led drug price negotiations and patent cliffs, that it will face over the medium term. Over the next five years, Johnson & Johnson should make significant progress across its pipeline, including with JNJ-6143. Johnson & Johnson's innovative abilities are one of the key reasons the stock is attractive.
And it's worth noting that the company's innovative medicines division could perform even better over the long run, given that it has spun off its slower-growing consumer health division and can focus more on its higher-growth pharmaceutical business. Johnson & Johnson's medtech unit adds even more depth and diversification to the business.
Finally, Johnson & Johnson remains one of the best dividend stocks on the market. With its streak of 64 consecutive years of payout increases, the healthcare leader is a Dividend King, or a stock with 50 or more straight annual dividend increases. Income seekers should stick with this stock for the long term.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*
Now, it’s worth noting Stock Advisor’s total average return is 790% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 19, 2026.
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.